Previous studies have detected IDO expression in tumor cells, blood vessels, stromal cells of NSCLC patients, as well as in dendritic cells (DCs) in the tumor environment and tumor-related lymph nodes in patients with LC (33). Here, IDO1 is linked to non-small cell lung carcinoma.